Company news
News Center
News center
202408-05
Congratulations to Lunarsum Pharmaceuticals on the National Medical Products Administration Approval of Famotidine Injection!
Lunarsum Pharma's Famotidine Injection has been officially approved for marketing.
Approval Number: H20244490
We welcome your inquiries and cooperation!
202401-18
Congratulations to Lunarsun on the Successful Status Upgrade of Mirabegron to “Active”!
Beijing Lunarsun Pharma is proud to announce that the imported API Mirabegron was successfully approved for turning into “Active ”on January 18, 2024.
Registration Number: Y20210000398
We warmly invite pharmaceutical manufacturers to reach out for collaboration opportunities.
202302-24
Welcome to Qingdao API Exhibition!
Qingdao API Exhibition
Time: December 14, 2023
Location: Qingdao
Booth number: N4 H12
Welcome new and old customers to visit and negotiate!
202203-29
Congratulations to Lunarsun Pharmaceuticals on the public announcement of their new active pharmaceutical ingredients, oseltamivir and everalen!
In March 2022, congratulations to Lairuisen Pharmaceuticals on successfully passing the evaluation and activating the registration status "A" for the import declaration of raw materials oseltamivir and efaviren. Welcome to cooperate.
